AI Article Synopsis
- The study examined 103 chronic myeloid leukaemia patients on imatinib (IM) and 57 patients with other disorders not on IM to assess potential heart-related side effects.
- There were no significant differences in heart symptoms, BNP levels, or echocardiogram results between the two groups, although peripheral edema was more common in the IM group.
- While IM did not lead to overall heart function decline, isolated instances of cardiotoxicity cannot be ruled out.
Article Abstract
We studied 103 consecutive patients with chronic myeloid leukaemia on treatment with imatinib (IM) and 57 patients with chronic myeloproliferative disorders not treated with IM in order to evaluate its cardiotoxicity. There was no statistical difference regarding cardiac symptoms and signs, BNP levels and echocardiographic measurements for IM and control groups, except for peripheral oedema, more frequent in the IM group. Four patients in the IM group presented a BNP level >100pg/ml, one of them with depressed LVEF. IM was not related to systematic deterioration of cardiac function, but there is still a possibility of isolated cases of cardiotoxicity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.leukres.2008.03.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!